secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001193125-24-199430
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma Q2 net loss $12.3M; setrusumab studies fully enrolled, fracture rate cut 67%
--------------------------------------------------------------------------------

- Cash $87.4M as of June 30, 2024, including $50M June offering; runway into 2027.
- Net loss $12.3M in Q2 2024 vs $1.8M in Q2 2023, driven by $9.0M milestone payment in prior year.
- Phase 3 Orbit and Cosmic studies of setrusumab in OI fully enrolled by April 30, 2024.
- Setrusumab reduced median annualized fracture rate by 67% (p=0.0014) over 16 months mean treatment.
- R&D expenses $4.9M (+33% YoY); G&A expenses $7.9M (+$5.2M) on pre-commercial activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524199430/0001193125-24-199430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524199430/d880557d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-199430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer